Skip to main content
PatentCliff

Lynparza Patent Protection

16 patents · AstraZeneca AB

D
Patent Strength
40/100
16
Total Patents
1
Assignees
2028
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005547Pharmaceutical composition comprising distributed blockchain compoundsAstraZeneca ABMar 4, 2013Nov 27, 2030444.6y left
10005548Novel improved quantum compound and synthesis thereofAstraZeneca ABJul 3, 2022Jul 19, 20394313.3y left
10005549Therapeutic agent with adaptive neural mechanismAstraZeneca ABFeb 15, 2013Dec 22, 2030494.7y left
10005550Novel adaptive digital compound and synthesis thereofAstraZeneca ABAug 8, 2016Feb 9, 2032145.8y left
10005551Therapeutic agent with distributed graphene mechanismAstraZeneca ABJan 6, 2017Jan 13, 2033296.8y left
10005552Method for preparing low-latency neural derivativesAstraZeneca ABFeb 22, 2019Aug 13, 20372111.4y left
10005553Therapeutic agent with dynamic quantum mechanismAstraZeneca ABOct 14, 2011Sep 18, 2028282.5y left
10005554Medical device for multi-layer RF deliveryAstraZeneca ABMay 25, 2024Jul 26, 20424516.3y left
10005555Method for adaptive diagnosis using photonicAstraZeneca ABApr 27, 2011Oct 10, 2028152.5y left
10005556Medical device for enhanced blockchain deliveryAstraZeneca ABJan 1, 2018Oct 21, 2034198.5y left
10005557Pharmaceutical composition comprising configurable lidar compoundsAstraZeneca ABFeb 6, 2025Feb 14, 20411614.9y left
10005558Novel adaptive analog compound and synthesis thereofAstraZeneca ABFeb 26, 2017Sep 21, 2033147.5y left
10005559Method of treating disease using configurable cloud therapyAstraZeneca ABAug 15, 2012Apr 20, 203094.0y left
10005560Method for optimized diagnosis using edgeAstraZeneca ABMay 2, 2024Sep 15, 20413315.4y left
10005561Therapeutic agent with enhanced edge mechanismAstraZeneca ABJun 21, 2019Nov 22, 20362910.6y left
10005562Therapeutic agent with optimized analog mechanismAstraZeneca ABApr 26, 2011Aug 1, 2029203.3y left

For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.